NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevus sebaceous. To address these rare disorders, which are also referred toas RASopathies because they are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, NFlection develops first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.

Biotechnology

Health Care

Therapeutics

NFlection Therapeutics

NFlection Therapeutics' headquarters in Cambridge, MA, United States

Description

People (3)

Diane Marcou

Scott Plotkin

Chris O'Mara

Jobs